FDA’s new pharmaceutical quality initiative: Knowledge-aided assessment & structured applications
Lawrence X. Yu, Andre Raw, Larisa Wu and 3 more
International Journal of Pharmaceutics: X · 2019
doi:10.1016/j.ijpx.2019.100010 (opens in a new tab)
We email you when a new notice or a question about this paper appears.
Abstract
This paper describes a new FDA’s pharmaceutical quality assessment system: Knowledge-aided Assessment & Structured Application (KASA). The KASA system is designed to: 1) capture and manage knowledge during the lifecycle of a drug product; 2) establish rules and algorithms for risk assessment, control, and communication; 3) perform computer-aided analyses of applications to compare regulatory standards and quality risks across applications and facilities; and 4) provide a structured assessment that minimizes text-based narratives and summarization of provided information. When fully developed and implemented, KASA will enrich the effectiveness, efficiency, and consistency of regulatory quality oversight through lifecycle management of products and facilities, and information sharing in a standardized and structured format. Ultimately, KASA will advance FDA’s focus on pharmaceutical quality, the foundation for ensuring the safety and efficacy of drugs. Keywords: Pharmaceutical quality, Knowledge management, Risk assessment, Risk control, Structured application
Abstract licence: CC BY-NC-ND
References6
6 more references, whose wording the paper’s licence keeps private.
Reads
Read by people on this page
None yet.
Checked or read by AI through naulon
None yet.
A person counts once a day per paper. We keep no cookie and no address: a reader is a hash that changes every day. Any month under five reads shows no number.
Are you an author?
Is this your paper?
Claim it to add your note and be paid when agents cite it. Free.